Jaguar Health to Present Crofelemer Results at SABCS 2024

Jaguar Health, Inc. has announced significant findings regarding crofelemer for treating cancer therapy-related diarrhea (CTD) in breast cancer patients. These results originate from the Phase 3 OnTarget trial, focusing on a prespecified subgroup of adult breast cancer patients. The data will be presented during the San Antonio Breast Cancer Symposium (SABCS) on December 11, 2024.

The OnTarget trial was initially aimed at various tumor types but did not meet its primary estimand for all tumors. However, the breast cancer subgroup showed promising outcomes for crofelemer. This has spurred Jaguar to prepare for engagement with the U.S. FDA and potential peer-reviewed publications.

Alongside the data presentation, Jaguar will partake in a patient advocacy event during SABCS, underlining its dedication to supportive care and patient engagement.